Company Press Releases Back
MedaSorb and CytoSorbents CEO Featured in Interviews by The Wall Street Transcript and CEO-CFO Interviews
Thursday July 16, 2009, 8:30 am EDT
CytoSorbents, Inc, and its parent MedaSorb Technologies Corporation, a medical device company in clinical trials treating severely septic patients with its proprietary blood purification CytoSorb(TM) cartridge, announced the online publication of two interviews with its CEO, Dr. Phillip Chan. The interviews cover Dr. Chan's perspectives on a variety of topics relating to the Company's cytokine filtering technology, current European sepsis trial, business model and ongoing strategy.
The first interview was conducted and published by The Wall Street Transcript, also known as TWST.com. An excerpt of the interview can be found at http://finance.yahoo.com/news/CytoSorb-Cytokine-Filter-Has-twst-2480925052.html?x=0&.v=3.
CytoSorbents has obtained distribution rights to the article and will make the interview transcript available to investors free of charge upon email request.
The second interview is published by CEO-CFO Interviews and is available online at http://ceocfointerviews.com/interviews/MSBT-MedaSorb.htm
About The Wall Street Transcript and CEO-CFO Interviews
The Wall Street Transcript, also known as TWST.com, publishes interviews with CEOs and research analysts. According to TWST.com, the print version of The Wall Street Transcript is distributed to thousands of financial libraries and investors, and they have well over 100,000 online readers per month.
CEO-CFO is a weekly Internet publication that provides detailed company profiles and CEO/CFO interviews, reaching the business and investment community worldwide as well as educational, military and government sources. According to CEO-CFO, they have over 100,000 readers monthly.
About CytoSorbents and CytoSorb™
CytoSorbents, Inc, with its parent MedaSorb Technologies Corporation, is in clinical trials to treat severe sepsis, often called "overwhelming infection," with a novel blood purification device called CytoSorb(TM). Severe sepsis is typically caused by bacterial infections like pneumonia, or viral infections like influenza. It afflicts more than 1 million people in the United States and an estimated 18 million people worldwide each year, killing one in every three patients despite the best treatment. In the United States, more die from severe sepsis than from either heart attacks, strokes or any single form of cancer. Much of the organ failure and mortality in severe sepsis is caused by the abnormal massive production of cytokines by the immune system, often called "cytokine storm." CytoSorb(TM) is a cartridge containing highly porous polymer beads that are designed to filter cytokines and treat potentially fatal cytokine storm. As blood is pumped through the CytoSorb(TM) cartridge using standard dialysis equipment, the beads bind and remove cytokines and other toxins from blood. The treated blood is then returned to the patient. The Company is currently conducting its European Sepsis Trial -- a multi-center, randomized, controlled clinical trial using its flagship CytoSorb(TM) device to treat up to 100 patients with severe sepsis in the setting of respiratory failure. Pending a successful trial, the Company will seek CE Mark approval and commercialization of CytoSorb(TM) in the European Union in 2010. CytoSorb(TM) is one of a number of different resins designed for different medical applications, including improved dialysis, the potential treatment of inflammatory and autoimmune disorders, treatment of rhabdomyolysis in trauma, drug detoxification and others.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation and CytoSorbents, Inc believe that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA and CE Mark approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Form 10-KSB filed with the SEC on April 10, 2009, which is available at http://www.sec.gov.
(732) 329-8885 ext. 816
Source: MedaSorb Technologies